Redefining Allogeneic Transplants & Cellular Therapy: Key Takeaways from EBMT 2025 - Episode 15
Unanswered Questions and the Future for Orca-T: What’s Next?
Panelists discuss how unanswered questions regarding long-term outcomes and potential late toxicities, along with the need for further evaluation in specific patient subgroups, highlight the importance of continued research to refine the use of ORCA-T across diverse populations.
Summary for Physicians: Unanswered Questions and Patient Subgroups for ORCA-T
The discussion addressed remaining questions and patient subgroups that need further evaluation with ORCA-T, as follows:
- Unanswered questions: Long-term outcomes, including durability of response and potential late toxicities, remain areas for further investigation.
- Patient subgroups: Specific subgroups, such as those with severe comorbidities or those in different age groups, still require additional study to fully understand how ORCA-T performs across diverse patient populations.
In conclusion, further research is needed to address these gaps and refine the treatment approach for different patient subgroups.
Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.
Related Content:
